Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김규보 | * |
dc.date.accessioned | 2018-12-07T16:30:22Z | - |
dc.date.available | 2018-12-07T16:30:22Z | - |
dc.date.issued | 2017 | * |
dc.identifier.issn | 1949-2553 | * |
dc.identifier.other | OAK-21351 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/247291 | - |
dc.description.abstract | Purpose: This study was conducted to evaluate the impact of radiation dose after margin involved resection in patients with extrahepatic bile duct cancer. Methods: Among the 251 patients who underwent curative resection followed by adjuvant chemoradiotherapy, 86 patients had either invasive carcinoma (n = 63) or carcinoma in situ (n = 23) at the resected margin. Among them, 54 patients received conventional radiation dose (40-50.4 Gy) and 32 patients received escalated radiation dose (54-56 Gy). Results: Escalated radiation dose was associated with improved locoregional control (5yr rate, 73.8% vs. 47.1%, p = 0.069), but not disease-free survival (5yr rate, 43.4% vs. 32.6%, p = 0.490) and overall survival (5yr rate, 40.6% vs. 29.6%, p = 0.348). In multivariate analysis for locoregional control, invasive carcinoma at the margin (HR 2.957, p = 0.032) and escalated radiation dose (HR 0.394, p = 0.047) were independent prognostic factors. No additional gastrointestinal toxicity was observed in escalated dose group. Conclusions: Delivery of radiation dose ≥ 54 Gy was well tolerated and associated with improved locoregional control, but not with overall survival after margin involved resection. Further validation study is warranted. © Kim et al. | * |
dc.language | English | * |
dc.publisher | Impact Journals LLC | * |
dc.subject | Extrahepatic bile duct cancer | * |
dc.subject | Postoperative radiotherapy | * |
dc.subject | R1 resection | * |
dc.subject | Radiation dose | * |
dc.title | Impact of radiation dose in postoperative radiotherapy after R1 resection for extrahepatic bile duct cancer: Long term results from a single institution | * |
dc.type | Article | * |
dc.relation.issue | 44 | * |
dc.relation.volume | 8 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 78076 | * |
dc.relation.lastpage | 78085 | * |
dc.relation.journaltitle | Oncotarget | * |
dc.identifier.doi | 10.18632/oncotarget.17368 | * |
dc.identifier.wosid | WOS:000412066700182 | * |
dc.identifier.scopusid | 2-s2.0-85030315119 | * |
dc.author.google | Kim B.H. | * |
dc.author.google | Chie E.K. | * |
dc.author.google | Kim K. | * |
dc.author.google | Jang J.-Y. | * |
dc.author.google | Kim S.W. | * |
dc.author.google | Oh D.-Y. | * |
dc.author.google | Bang Y.-J. | * |
dc.author.google | Ha S.W. | * |
dc.contributor.scopusid | 김규보(8213302900) | * |
dc.date.modifydate | 20240222162403 | * |